VBI Vaccines (NASDAQ:VBIV) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a research note issued to investors on Saturday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

VBI Vaccines Price Performance

VBIV opened at $0.69 on Friday. The stock’s 50-day moving average price is $0.61 and its 200 day moving average price is $0.62. VBI Vaccines has a 12-month low of $0.45 and a 12-month high of $2.90.

VBI Vaccines (NASDAQ:VBIV) last posted its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.02). VBI Vaccines had a negative return on equity of 525.42% and a negative net margin of 881.79%. The firm had revenue of $1.21 million for the quarter, compared to analyst estimates of $2.85 million. Analysts expect that VBI Vaccines will post -1.23 earnings per share for the current fiscal year.

About VBI Vaccines

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.